Once an oncologist decides a patient needs chemotherapy, Moffitt will test for PGx markers that might hinder his or her ability to metabolize anti-vomiting and pain meds.
The partners will study the association between genetic variants and chemotherapy side effects to find biomarkers for an upcoming NGS pharmacogenomics panel.
The conditional licensure is the latest for the firm's FISH-based HPV-Associated test for cervical cancer.
The company borrowed $2 million pursuant to an amendment to a $12 million credit agreement. It also said that it has until June 19 to meet certain listing requirements.
About 19 million ACPN members will now have access to Cancer Genetics' cancer diagnostic services through their insurers.
Revenue from the firm's ResponseDX test jumped 16 percent in the fourth quarter of 2014 and 22 percent for the full year.
The company's biopharma business grew 280 percent year over year, including contributions from Gentris, which Cancer Genetics bought last summer.
The company drew a first tranche of $8.5 million from the credit facility in July and has $2 million remaining on the term loan commitment.
The technical-only testing service leverages Ventana's digital pathology technology.
The decision opens up the largest market in the country to the firm's lymphoma and leukemia testing services.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.